HUHUTECH International Group Inc. (HUHU) Joins Bid for >RMB 60M Fab Gas System Project

HUHUTECH International Group Inc. (HUHU) furnished an SEC Form 6-K — earnings release. Exhibit 99.3 HUHUTECH Reports 8.6% Revenue Growth for First Half of 2026, with New U.S., Germany, and Singapore Operations Contributing $3.7 Million Three markets opened within the past 18 months accounted for 34.6% of total revenue; average system integration contract value doub

TechnipFMC (FTI) signed a memorandum of understanding with BP to supply high-pressure subsea production systems for BP's future developments in the U.S. Gulf. FTI's stock rose 1.6% on the news. The agreement establishes a framework for future collaboration.

TD Cowen kept its Hold rating on Moderna (MRNA) with a $90 price target, implying a 62.8% downside from the Oct 20 close. The firm cited positive clinical developments and resilient revenue projections for Moderna's COVID-19 and INT franchises.

Roivant Sciences (ROIV) reported positive Phase III results for brepocitinib in treating uveitis, with over 60% of patients achieving steroid-free quiescence. The drug showed improvement in macular edema and visual function. Roivant plans to submit a supplemental new drug application in 2027 and will discuss commercial opportunities at an Investor Day.

TD Cowen reaffirmed a Buy rating on Incyte with a $140 price target, suggesting a 20.1% upside from the Oct 20 close. Jakafi sales grew 8% YoY to $2.59B in 2023, with peak U.S. sales projected to exceed $3B. Incyte's pipeline, including Opzelura, is expected to drive future revenue growth.

Piper Sandler kept its Overweight rating on Capital One Financial, setting a $269 price target, implying a 33.5% upside from the Oct 20 close. The firm cites strong post-integration earnings, with a 21% ROTCE, and resilient credit quality, with a 3.98% NCO rate and $225M in reserve releases.